Australian drug development company Kazia Therapeutics Limited (NASDAQ:KZIA) on Monday announced the sale of all intellectual property and trademark rights for Cantrixil to Swedish development company Vivesto AB (STO:VIVE) for USD1m.
This agreement provides Kazia with non-dilutive funding to support its proprietary, clinical-stage pipeline.
Vivesto previously licensed the global development and commercialisation rights for Cantrixil from Kazia in March 2021. Initially intended for ovarian cancer, Vivesto has shifted its focus to preclinical exploration of Cantrixil for haematological cancers.
Cantrixil is a legacy asset in Kazia's portfolio, featuring TRXE-002-01, a third-generation benzopyran SMETI inhibitor encapsulated in α-cyclodextrin.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne